Search companies

Live

COMPUMEDICS LIMITED (ASX: CMP)

Health care · News and insights

Price unavailable

Latest CMP announcements

Announcement Insights

Compumedics Targets Faster FY27 Growth After Missing FY26 Guidance, While Seeking Technology Partners

Compumedics is targeting double-digit sales growth and faster EBITDA growth in FY27 after acknowledging it missed its FY26 revenue and EBITDA guidance, despite reporting record FY26 sales, up 18.5%, and EBITDA growth of 74%. It is also pursuing partnerships, licensing and strategic investment across five programs, with the first US Somfit D shipment made in November; no transaction has been agreed, and the company says none is certain to proceed.

Updated 11 Nov 2026, 09:57 AM Sydney time
Share
SourcesInvestor Update Nov-26Appointment of Strategic AdvisorAppointment of Chief Financial Officer & Company SecretaryChair's Address to ShareholdersResults of Meeting
Comments

Compumedics Launches Five-Program Push to Unlock Value From Medical Technology

2026-11-11 · Health care

CMP: $0.250 +4.17% · MC: $48M

Compumedics is pursuing partnerships, licensing, co-development and strategic investment across five programs focused on Somfit, DWL and OrionMEG, aiming to accelerate commercialisation of its existing research and development; it says no transaction has been agreed and none is certain to proceed. The investor update also says the first Somfit D shipment to the US occurred in November, while the company acknowledges it missed FY26 revenue and EBITDA guidance. In FY27, Compumedics is targeting double-digit sales growth and EBITDA growth faster than sales.

Updated 2026-11-11 09:57
Share
SourcesInvestor Update Nov-26
Comments

Compumedics Taps US Healthcare Deal-Maker To Explore Somfit Partnerships

2026-11-06 · Health care

CMP: $0.240 +4.35% · MC: $48M

Compumedics has appointed former Fortune 5 healthcare M&A executive Syed Husain to lead a program exploring partnership, licensing, distribution and strategic investment opportunities for Somfit and NEXUS 360 in the US. The company says the approach is intended to realise value through partnerships or strategic investment rather than issuing new shares, and expects to make two to three further appointments across its value-realisation programs by the end of the March 2027 quarter.

Updated 2026-11-06 10:08
Share
SourcesAppointment of Strategic Advisor
Comments

Compumedics Names Troy Lamb CFO In Planned Finance Leadership Succession

2026-10-30 · Health care

CMP: $0.240 +2.13% · MC: $48M

Compumedics has appointed Deputy CFO Troy Lamb as CFO and Company Secretary from 1 November, succeeding David Lawson, who will remain Finance Director and continue contributing to the company’s strategy and growth initiatives. Lamb joined Compumedics in March 2025 and worked with the finance team through its record FY26 result.

Updated 2026-10-30 10:57
Share
SourcesAppointment of Chief Financial Officer & Company Secretary
Comments

Compumedics Targets Double-Digit FY27 Growth After Record Sales

2026-10-29 · Health care

CMP: $0.235 +2.17% · MC: $48M

Compumedics reported record FY26 sales, up 18.5%, while EBITDA rose 74% and cash from operations increased from $0.4 million to $6.6 million. For FY27, it aims for double-digit sales growth and faster EBITDA growth, with over $28 million of orders to deliver; these are company objectives, not a forecast. At its AGM, shareholders re-elected Rod North and adopted the Remuneration Report.

Updated 2026-10-29 15:54
Share
SourcesChair's Address to ShareholdersResults of Meeting
Comments